Ina Koch

Dr. Ina Koch


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OBOlga Bermudez
Olga Bermudez
EHElisabeth Hennen
Elisabeth Hennen
IKIna Koch
Ina Koch
MLMichael Lindner
Michael Lindner
OEOliver Eickelberg
Oliver Eickelberg
Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1-3), have recently been found to be reactivated in NSCLC, their functional role remains unclear. Here, we hypothesized that Shh/Gli1-3 could mediate NSCLC autonomous proliferation and epithelial/stromal signaling in the tumoral tissue. In this context, we have investigated the activity of Shh/Gli1-3 signaling in NSCLC in both, cancer and stromal cells. We report here that inhibition of Shh signaling induces a significant decrease in the proliferation of NSCLC cells. This effect is mediated by Gli1 and Gli2, but not Gli3, through regulation of cyclin D1 and cyclin D2 expression. While exogenous Shh was unable to induce signaling in either A549 lung adenocarcinoma or H520 lung squamous carcinoma cells, both cells were found to secrete Shh ligand, which induced fibroblast proliferation, survival, migration, invasion, and collagen synthesis. Furthermore, Shh secreted by NSCLC mediates the production of proangiogenic and metastatic factors in lung fibroblasts. Our results thus provide evidence that Shh plays an important role in mediating epithelial/mesenchymal crosstalk in NSCLC. While autonomous Gli activity controls NSCLC proliferation, increased Shh expression by NSCLC is associated with fibroblast activation in tumor-associated stroma. Our study highlights the relevance of studying stromal-associated cells in the context of NSCLC regarding new prognosis and therapeutic options.

22 May 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
AJAaron Javitt
Aaron Javitt
MSMerav D. Shmueli
Merav D. Shmueli
MKMatthias P. Kramer
Matthias P. Kramer
AKAleksandra A. Kolodziejczyk
Aleksandra A. Kolodziejczyk
ICIvan J. Cohen
Ivan J. Cohen
YMYifat Merbl
Yifat Merbl

26 October 2021 in eLife
Verified
Journal Article
Open access
MHMarinus Huber
Marinus Huber
KKKosmas V Kepesidis
Kosmas V Kepesidis
LVLiudmila Voronina
Liudmila Voronina
FFFrank Fleischmann
Frank Fleischmann
EFErnst Fill
Ernst Fill
MZMihaela Zigman
Mihaela Zigman
Recent omics analyses of human biofluids provide opportunities to probe selected species of biomolecules for disease diagnostics. Fourier-transform infrared (FTIR) spectroscopy investigates the full repertoire of molecular species within a sample at once. Here, we present a multi-institutional study in which we analysed infrared fingerprints of plasma and serum samples from 1639 individuals with different solid tumours and carefully matched symptomatic and non-symptomatic reference individuals. Focusing on breast, bladder, prostate, and lung cancer, we find that infrared molecular fingerprinting is capable of detecting cancer: training a support vector machine algorithm allowed us to obtain binary classification performance in the range of 0.78–0.89 (area under the receiver operating characteristic curve [AUC]), with a clear correlation between AUC and tumour load. Intriguingly, we find that the spectral signatures differ between different cancer types. This study lays the foundation for high-throughput onco-IR-phenotyping of four common cancers, providing a cost-effective, complementary analytical tool for disease recognition.

5 May 2023 in The EMBO Journal
Verified
Journal Article
Open access
Uwe SchwartzUwe Schwartz
Uwe Schwartz
MPMaria Llamazares Prada
Maria Llamazares Prada
SPStephanie T Pohl
Stephanie T Pohl
MRMandy Richter
Mandy Richter
RTRaluca Tamas
Raluca Tamas
Renata JurkowskaRenata Jurkowska
Renata Jurkowska
Patients with chronic obstructive pulmonary disease (COPD) are still waiting for curative treatments. Considering its environmental cause, we hypothesized that COPD will be associated with altered epigenetic signaling in lung cells. We generated genome-wide DNA methylation maps at single CpG resolution of primary human lung fibroblasts (HLFs) across COPD stages. We show that the epigenetic landscape is changed early in COPD, with DNA methylation changes occurring predominantly in regulatory regions. RNA sequencing of matched fibroblasts demonstrated dysregulation of genes involved in proliferation, DNA repair, and extracellular matrix organization. Data integration identified 110 candidate regulators of disease phenotypes that were linked to fibroblast repair processes using phenotypic screens. Our study provides high-resolution multi-omic maps of HLFs across COPD stages. We reveal novel transcriptomic and epigenetic signatures associated with COPD onset and progression and identify new candidate regulators involved in the pathogenesis of chronic lung diseases. The presence of various epigenetic factors among the candidates demonstrates that epigenetic regulation in COPD is an exciting research field that holds promise for novel therapeutic avenues for patients.

7 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMarkus Beutler
Markus Beutler
SPSara Plesnik
Sara Plesnik
MMMarina Mihalic
Marina Mihalic
LOLaura Olbrich
Laura Olbrich
NHNorbert Heinrich
Norbert Heinrich
HHHarald Hoffmann
Harald Hoffmann
Rapid diagnosis of tuberculosis (TB) and antibiotic resistances are imperative to initiate effective treatment and to stop transmission of the disease. A new generation of more sensitive, automated molecular TB diagnostic tests has been recently launched giving microbiologists more choice between several assays with the potential to detect resistance markers for rifampicin and isoniazid. In this study, we determined analytical sensitivities as 95% limits of detection (LoD95) for Xpert MTB/Rif Ultra (XP-Ultra) and BD-MAX MDR-TB (BD-MAX) as two representatives of the new test generation, in comparison to the conventional FluoroType MTB (FT-MTB). Test matrices used were physiological saline solution, human and a mucin-based artificial sputum (MUCAS) each spiked with Mycobacterium tuberculosis in declining culture- and qPCR-controlled concentrations. With BD-MAX, XP-Ultra, and FT-MTB, we measured LoD95TB values of 2.1 cfu/ml (CI95%: 0.9–23.3), 3.1 cfu/ml (CI95%: 1.2–88.9), and 52.1 cfu/ml (CI95%: 16.7–664.4) in human sputum; of 6.3 cfu/ml (CI95%: 2.9–31.8), 1.5 cfu/ml (CI95%: 0.7–5.0), and 30.4 cfu/ml (CI95%: 17.4–60.7) in MUCAS; and of 2.3 cfu/ml (CI95%: 1.1–12.0), 11.5 cfu/ml (CI95%: 5.6–47.3), and 129.1 cfu/ml (CI95%: 82.8–273.8) in saline solution, respectively. LoD95 of resistance markers were 9 to 48 times higher compared to LoD95TB. BD-MAX and XP-Ultra have an equal and significantly increased analytical sensitivity compared to conventional tests. MUCAS resembled human sputum, while both yielded significantly different results than normal saline. MUCAS proved to be suitable for quality control of PCR assays for TB diagnostics.

22 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MLMaria Llamazares-Prada
Maria Llamazares-Prada
EEElisa Espinet
Elisa Espinet
VMVedrana Mijošek
Vedrana Mijošek
Uwe SchwartzUwe Schwartz
Uwe Schwartz
PLPavlo Lutsik
Pavlo Lutsik
Renata JurkowskaRenata Jurkowska
Renata Jurkowska
Complexity of lung microenvironment and changes in cellular composition during disease make it exceptionally hard to understand molecular mechanisms driving development of chronic lung diseases. Although recent advances in cell type–resolved approaches hold great promise for studying complex diseases, their implementation relies on local access to fresh tissue, as traditional tissue storage methods do not allow viable cell isolation. To overcome these hurdles, we developed a versatile workflow that allows storage of lung tissue with high viability, permits thorough sample quality check before cell isolation, and befits sequencing-based profiling. We demonstrate that cryopreservation enables isolation of multiple cell types from both healthy and diseased lungs. Basal cells from cryopreserved airways retain their differentiation ability, indicating that cellular identity is not altered by cryopreservation. Importantly, using RNA sequencing and EPIC Array, we show that gene expression and DNA methylation signatures are preserved upon cryopreservation, emphasizing the suitability of our workflow for omics profiling of lung cells. Moreover, we obtained high-quality single-cell RNA-sequencing data of cells from cryopreserved human lungs, demonstrating that cryopreservation empowers single-cell approaches. Overall, thanks to its simplicity, our workflow is well suited for prospective tissue collection by academic collaborators and biobanks, opening worldwide access to viable human tissue.